Literature DB >> 20555067

Locally recurrent or metastatic breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.

F Cardoso1, E Senkus-Konefka, L Fallowfield, A Costa, M Castiglione.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2010        PMID： 20555067     DOI： 10.1093/annonc/mdq160

Source DB:  PubMed          Journal:  Ann Oncol        ISSN： 0923-7534            Impact factor:   32.976


× No keyword cloud information.
  41 in total

Review 1.  Pegylated liposomal doxorubicin: a review of its use in metastatic breast cancer, ovarian cancer, multiple myeloma and AIDS-related Kaposi's sarcoma.

Authors:  Sean T Duggan; Gillian M Keating
Journal:  Drugs       Date:  2011-12-24       Impact factor: 9.546

2.  Emerging trends in the treatment of triple-negative breast cancer in Canada: a survey.

Authors:  S Verma; L Provencher; R Dent
Journal:  Curr Oncol       Date:  2011-08       Impact factor: 3.677

3.  Breast cancer cells promote osteoblastic differentiation via Sema 3A signaling pathway in vitro.

Authors:  Wei-Wei Shen; Wu-Gui Chen; Fu-Zhou Liu; Xu Hu; Hong-Kai Wang; Ying Zhang; Tong-Wei Chu
Journal:  Int J Clin Exp Pathol       Date:  2015-02-01

4.  Magnitude of risks and benefits of the addition of bevacizumab to chemotherapy for advanced breast cancer patients: Meta-regression analysis of randomized trials.

Authors:  Federica Cuppone; Emilio Bria; Vanja Vaccaro; Fabio Puglisi; Alessandra Fabi; Isabella Sperduti; Paolo Carlini; Michele Milella; Cecilia Nisticò; Michelangelo Russillo; Paola Papaldo; Gianluigi Ferretti; Matti Aapro; Diana Giannarelli; Francesco Cognetti
Journal:  J Exp Clin Cancer Res       Date:  2011-05-12

Review 5.  Bevacizumab: a review of its use in combination with paclitaxel or capecitabine as first-line therapy for HER2-negative metastatic breast cancer.

Authors:  Katherine F Croom; Sohita Dhillon
Journal:  Drugs       Date:  2011-11-12       Impact factor: 9.546

6.  Final results of a phase II study of paclitaxel, bevacizumab, and gemcitabine as first-line therapy for patients with HER2-negative metastatic breast cancer.

Authors:  J Salvador; L Manso; J de la Haba; A Jaen; E Ciruelos; M C de Villena; M Gil; A Murias; A Galan; C Jara; J Bayo; J M Baena; J Casal; J R Mel; I Blancas; P Sanchez Rvira
Journal:  Clin Transl Oncol       Date:  2014-08-14       Impact factor: 3.405

7.  Metronomic methotrexate and cyclophosphamide after carboplatin included adjuvant chemotherapy in triple negative breast cancer: a phase III study.

Authors:  Khalid E Nasr; Mohammed A Osman; Mohammad S Elkady; Mahmoud A Ellithy
Journal:  Ann Transl Med       Date:  2015-11

Review 8.  The place for eribulin in the treatment of metastatic breast cancer.

Authors:  William J Gradishar
Journal:  Curr Oncol Rep       Date:  2011-02       Impact factor: 5.075

9.  Using breast cancer cell CXCR4 surface expression to predict liposome binding and cytotoxicity.

Authors:  Peng Guo; Jin-Oh You; Jiang Yang; Marsha A Moses; Debra T Auguste
Journal:  Biomaterials       Date:  2012-08-09       Impact factor: 12.479

10.  The inconsistency of molecular subtypes between primary foci and metastatic axillary lymph nodes in Luminal A breast cancer patients among Chinese women, an indication for chemotherapy?

Authors:  Yadong Sun; Xiaofeng Liu; Shude Cui; Lianfang Li; Peiqi Tian; Shanqing Liu; Yong Li; Mengmeng Yin; Chongjian Zhang; Qixin Mao; Jiaxiang Wang
Journal:  Tumour Biol       Date:  2016-01-20
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.